2B23 image
Deposition Date 2005-09-16
Release Date 2006-09-19
Last Version Date 2024-10-16
Entry Detail
PDB ID:
2B23
Title:
Human estrogen receptor alpha ligand-binding domain and a glucocorticoid receptor-interacting protein 1 NR box II peptide
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
(Taxon ID: )
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.27
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Estrogen receptor
Gene (Uniprot):ESR1
Mutations:S537Y
Chain IDs:A, B
Chain Length:257
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nuclear receptor coactivator 2
Gene (Uniprot):NCOA2
Chain IDs:C, D
Chain Length:13
Number of Molecules:2
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
CME A CYS S,S-(2-HYDROXYETHYL)THIOCYSTEINE
Primary Citation
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
Nat.Chem.Biol. 4 241 247 (2008)
PMID: 18344977 DOI: 10.1038/nchembio.76

Abstact

Our understanding of how steroid hormones regulate physiological functions has been significantly advanced by structural biology approaches. However, progress has been hampered by misfolding of the ligand binding domains in heterologous expression systems and by conformational flexibility that interferes with crystallization. Here, we show that protein folding problems that are common to steroid hormone receptors are circumvented by mutations that stabilize well-characterized conformations of the receptor. We use this approach to present the structure of an apo steroid receptor that reveals a ligand-accessible channel allowing soaking of preformed crystals. Furthermore, crystallization of different pharmacological classes of compounds allowed us to define the structural basis of NFkappaB-selective signaling through the estrogen receptor, thus revealing a unique conformation of the receptor that allows selective suppression of inflammatory gene expression. The ability to crystallize many receptor-ligand complexes with distinct pharmacophores allows one to define structural features of signaling specificity that would not be apparent in a single structure.

Legend

Protein

Chemical

Disease

Primary Citation of related structures